Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 20/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | HTR1E | P28566 | 1/20 | 1.00 |
| ▸ | HTR1F | P30939 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
| ▸ | CCR5 | P51681 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705002 | 0.81 | CCR2 (0.67) | CCR2HTR1ADRD2HTR1BHTR2A | |
| SCHEMBL12951632 | 0.79 | CCR2 (0.81) | CCR2HTR1ADRD2HTR1BHTR2A | |
| SCHEMBL7703004 | 0.78 | CCR2 (0.76) | CCR2HTR1ADRD2HTR1BHTR2A | |
| SCHEMBL5705215 | 0.78 | CCR2 (0.73) | CCR2HTR1ADRD2HTR1BHTR2A | |
| SCHEMBL5704961 | 0.76 | CCR2 (0.61) | CCR2HTR1ADRD2HTR1BHTR2A | |
| SCHEMBL9673927 | 0.74 | CCR2 (0.71) | CCR2HTR1ADRD2HTR1BHTR2A | |
| SCHEMBL9673934 | 0.74 | CCR2 (0.71) | CCR2HTR1ADRD2HTR1BHTR2A | |
| SCHEMBL88313 | 0.74 | CCR2 (0.81) | CCR2HTR1ADRD2HTR1BHTR2A | |
| SCHEMBL88314 | 0.74 | CCR2 (0.81) | CCR2HTR1ADRD2HTR1BHTR2A | |
| SCHEMBL6133421 | 0.73 | SLC6A4 (0.71) | CCR2HTR1ADRD2HTR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514937-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2026-01-06 | — | — | US | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| US-20240299598-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | WASHINGTON UNIVERSITY (US) | 2024-09-12 | — | — | US | disclosed |
| US-12016935-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | VIVORIAN THERAPEUTICS N.V | 2022-03-22 | — | — | US | disclosed |
| CN-108218849-B | Novel inhibitors | 维沃永治疗公众有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | CCR2 2559/4885HTR1A 1228/4885DRD2 1609/4885 |
| US-12016935-B2 | Methods for detecting CCR2 receptors | CCR2, CCR1, CCR5 | CCR2 1/4885HTR1A 1059/4885DRD2 2085/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | CCR2 4360/4885HTR1A 2812/4885DRD2 3492/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | CCR2 3990/4885HTR1A 3218/4885DRD2 1886/4885 |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | QPCT, QPCTL, GLUL | CCR2 4212/4885HTR1A 3764/4885DRD2 4565/4885 |
| US-20240299598-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | CCR2, CCR1, CCR5 | CCR2 1/4885HTR1A 1059/4885DRD2 2085/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | CCR2 4242/4885HTR1A 2062/4885DRD2 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.